Cargando…
Sarcopenia screening in elderly with Alzheimer’s disease: performances of the SARC-F-3 and MSRA-5 questionnaires
BACKGROUND: The 3-item SARC-F (SARC-F-3) and the 5-item Mini Sarcopenia Risk Assessment (MSRA-5) questionnaires have been recently proposed to screen elderly people regarding the risk of sarcopenia. However, no studies have investigated their performances in Alzheimer’s disease (AD). METHODS: We con...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482268/ https://www.ncbi.nlm.nih.gov/pubmed/36114480 http://dx.doi.org/10.1186/s12877-022-03441-5 |
_version_ | 1784791418017939456 |
---|---|
author | Bramato, Giulia Barone, Roberta Barulli, Maria Rosaria Zecca, Chiara Tortelli, Rosanna Filardi, Marco Logroscino, Giancarlo |
author_facet | Bramato, Giulia Barone, Roberta Barulli, Maria Rosaria Zecca, Chiara Tortelli, Rosanna Filardi, Marco Logroscino, Giancarlo |
author_sort | Bramato, Giulia |
collection | PubMed |
description | BACKGROUND: The 3-item SARC-F (SARC-F-3) and the 5-item Mini Sarcopenia Risk Assessment (MSRA-5) questionnaires have been recently proposed to screen elderly people regarding the risk of sarcopenia. However, no studies have investigated their performances in Alzheimer’s disease (AD). METHODS: We conducted a single-center observational study, including 130 consecutive AD patients (mean age: 70.71 ± 8.50 y, 54.6% women) who attended a center for neurodegenerative diseases. Sarcopenia was diagnosed using the European Working Group on Sarcopenia in Older People of 2010 (EWGSOP1) and of 2018 (EWGSOP2) criteria. Sensitivity, specificity, positive and negative likelihood ratio, and the area under the receiver operating characteristic curve (AUC) were used to assess the diagnostic performance of SARC-F-3 and MSRA-5. RESULTS: SARC-F-3 showed a sensitivity of 9.7%, a specificity of 82.8% and an AUC of 0.41 using EWGSOP1, whereas the sensitivity was of 16.7%, specificity of 84.7% and AUC of 0.58 using EWGSOP2. The MSRA-5 displayed a sensitivity of 3.2%, a specificity of 89.9% and an AUC of 0.41 using EWGSOP1, whereas sensitivity was of 0%, specificity of 91.1% and the AUC of 0.55 using EWGSOP2 criteria. The questionnaires showed a moderate agreement (Cohen's k = 0.53). CONCLUSIONS: In our sample of AD patients, a sizable number of sarcopenic individuals were misidentified by SARC-F-3 and MSRA-5, making those questionnaires unsuitable for sarcopenia screening. Considering that sarcopenia has a high prevalence in dementia and that its correct and timely identification is paramount for optimal management of patients, the development and validation of an ad-hoc sarcopenia screening tool for AD patients is highly desirable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-022-03441-5. |
format | Online Article Text |
id | pubmed-9482268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94822682022-09-18 Sarcopenia screening in elderly with Alzheimer’s disease: performances of the SARC-F-3 and MSRA-5 questionnaires Bramato, Giulia Barone, Roberta Barulli, Maria Rosaria Zecca, Chiara Tortelli, Rosanna Filardi, Marco Logroscino, Giancarlo BMC Geriatr Research BACKGROUND: The 3-item SARC-F (SARC-F-3) and the 5-item Mini Sarcopenia Risk Assessment (MSRA-5) questionnaires have been recently proposed to screen elderly people regarding the risk of sarcopenia. However, no studies have investigated their performances in Alzheimer’s disease (AD). METHODS: We conducted a single-center observational study, including 130 consecutive AD patients (mean age: 70.71 ± 8.50 y, 54.6% women) who attended a center for neurodegenerative diseases. Sarcopenia was diagnosed using the European Working Group on Sarcopenia in Older People of 2010 (EWGSOP1) and of 2018 (EWGSOP2) criteria. Sensitivity, specificity, positive and negative likelihood ratio, and the area under the receiver operating characteristic curve (AUC) were used to assess the diagnostic performance of SARC-F-3 and MSRA-5. RESULTS: SARC-F-3 showed a sensitivity of 9.7%, a specificity of 82.8% and an AUC of 0.41 using EWGSOP1, whereas the sensitivity was of 16.7%, specificity of 84.7% and AUC of 0.58 using EWGSOP2. The MSRA-5 displayed a sensitivity of 3.2%, a specificity of 89.9% and an AUC of 0.41 using EWGSOP1, whereas sensitivity was of 0%, specificity of 91.1% and the AUC of 0.55 using EWGSOP2 criteria. The questionnaires showed a moderate agreement (Cohen's k = 0.53). CONCLUSIONS: In our sample of AD patients, a sizable number of sarcopenic individuals were misidentified by SARC-F-3 and MSRA-5, making those questionnaires unsuitable for sarcopenia screening. Considering that sarcopenia has a high prevalence in dementia and that its correct and timely identification is paramount for optimal management of patients, the development and validation of an ad-hoc sarcopenia screening tool for AD patients is highly desirable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-022-03441-5. BioMed Central 2022-09-17 /pmc/articles/PMC9482268/ /pubmed/36114480 http://dx.doi.org/10.1186/s12877-022-03441-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Bramato, Giulia Barone, Roberta Barulli, Maria Rosaria Zecca, Chiara Tortelli, Rosanna Filardi, Marco Logroscino, Giancarlo Sarcopenia screening in elderly with Alzheimer’s disease: performances of the SARC-F-3 and MSRA-5 questionnaires |
title | Sarcopenia screening in elderly with Alzheimer’s disease: performances of the SARC-F-3 and MSRA-5 questionnaires |
title_full | Sarcopenia screening in elderly with Alzheimer’s disease: performances of the SARC-F-3 and MSRA-5 questionnaires |
title_fullStr | Sarcopenia screening in elderly with Alzheimer’s disease: performances of the SARC-F-3 and MSRA-5 questionnaires |
title_full_unstemmed | Sarcopenia screening in elderly with Alzheimer’s disease: performances of the SARC-F-3 and MSRA-5 questionnaires |
title_short | Sarcopenia screening in elderly with Alzheimer’s disease: performances of the SARC-F-3 and MSRA-5 questionnaires |
title_sort | sarcopenia screening in elderly with alzheimer’s disease: performances of the sarc-f-3 and msra-5 questionnaires |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482268/ https://www.ncbi.nlm.nih.gov/pubmed/36114480 http://dx.doi.org/10.1186/s12877-022-03441-5 |
work_keys_str_mv | AT bramatogiulia sarcopeniascreeninginelderlywithalzheimersdiseaseperformancesofthesarcf3andmsra5questionnaires AT baroneroberta sarcopeniascreeninginelderlywithalzheimersdiseaseperformancesofthesarcf3andmsra5questionnaires AT barullimariarosaria sarcopeniascreeninginelderlywithalzheimersdiseaseperformancesofthesarcf3andmsra5questionnaires AT zeccachiara sarcopeniascreeninginelderlywithalzheimersdiseaseperformancesofthesarcf3andmsra5questionnaires AT tortellirosanna sarcopeniascreeninginelderlywithalzheimersdiseaseperformancesofthesarcf3andmsra5questionnaires AT filardimarco sarcopeniascreeninginelderlywithalzheimersdiseaseperformancesofthesarcf3andmsra5questionnaires AT logroscinogiancarlo sarcopeniascreeninginelderlywithalzheimersdiseaseperformancesofthesarcf3andmsra5questionnaires |